Avapritinib for preventing leukemia relapse after transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a pill called avapritinib to keep leukemia from coming back after a stem cell transplant. It is for people with AML that has a KIT mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older.
- You have a type of leukemia called AML (acute myeloid leukemia) that has a KIT mutation.
- You have received your first stem cell transplant from a donor.
- Your leukemia is in remission (no signs of cancer) after the transplant.
- Your blood counts are good enough (for example, enough infection-fighting cells, platelets, and red blood cells).
- You have not had other cancers that need treatment, and you do not have serious organ problems or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
This trial tests a new targeted therapy for a specific type of leukemia (CBF-AML with a KIT gene change) in people who have not yet had treatment. The goal is to see if adding a KIT inhibitor to standard chemotherapy can improve outcomes.
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.